A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
Primary Purpose
Alagille Syndrome
Status
Approved for marketing
Phase
Locations
United States
Study Type
Expanded Access
Intervention
maralixibat
Sponsored by
About this trial
This is an expanded access trial for Alagille Syndrome focused on measuring Liver Disease, ALGS, Maralixibat, Bile Duct Diseases, Digestive System Diseases, Biliary Tract Diseases, Cholestasis, Pruritis
Eligibility Criteria
Inclusion Criteria:
- Informed consent and assent provided, as applicable, per Institutional Review Board (IRB) or Ethics Committee (EC)
- Clinical and/or genetic diagnosis of ALGS
- Male or female participants aged >12 months and ≥5 kg with clinically significant cholestatic pruritus associated with ALGS
- Willingness to adhere to an acceptable method of contraception until treatment discontinuation by females of childbearing potential who are sexually active or who become sexually active during the program
- No other therapeutic options or access to any ongoing ALGS clinical trials
Exclusion Criteria:
- Diagnosis with a cholestatic liver disease other than ALGS
- Female who is pregnant or breastfeeding
- Clinically significant cardiovascular, hepatic, gastro-intestinal, pulmonary, neurologic, infectious or renal disease or other medical condition that, in the opinion of the physician or Medical Monitor, would preclude participation in the program
- Past medical history of compensated or decompensated cirrhosis
- Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of maralixibat or its mode of action
Sites / Locations
- University of California, Los Angeles
- Stanford University
- University of California San Francisco
- Georgetown University
- Advent Health
- Children's Healthcare of Atlanta/Emory University
- Ann & Robert H. Lurie Children's Hospital
- Ochsner Clinic Foundation
- University of Minnesota
- The Children's Hospital at Montefiore
- University of Oklahoma
- Baylor College of Medicine
- University of Virginia
- Medical College of Wisconsin
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT04530994
First Posted
August 25, 2020
Last Updated
October 12, 2021
Sponsor
Mirum Pharmaceuticals, Inc.
Collaborators
Clinigen, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04530994
Brief Title
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
Official Title
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome
Study Type
Expanded Access
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Approved for marketing
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mirum Pharmaceuticals, Inc.
Collaborators
Clinigen, Inc.
4. Oversight
5. Study Description
Brief Summary
An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.
Detailed Description
The objective of this EAP is to provide access to maralixibat for eligible ALGS patients with cholestatic pruritus. Participants will be treated with 400 µg/kg/day with safety and tolerability evaluated on an ongoing basis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alagille Syndrome
Keywords
Liver Disease, ALGS, Maralixibat, Bile Duct Diseases, Digestive System Diseases, Biliary Tract Diseases, Cholestasis, Pruritis
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
maralixibat
Intervention Description
Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Months
Eligibility Criteria
Inclusion Criteria:
Informed consent and assent provided, as applicable, per Institutional Review Board (IRB) or Ethics Committee (EC)
Clinical and/or genetic diagnosis of ALGS
Male or female participants aged >12 months and ≥5 kg with clinically significant cholestatic pruritus associated with ALGS
Willingness to adhere to an acceptable method of contraception until treatment discontinuation by females of childbearing potential who are sexually active or who become sexually active during the program
No other therapeutic options or access to any ongoing ALGS clinical trials
Exclusion Criteria:
Diagnosis with a cholestatic liver disease other than ALGS
Female who is pregnant or breastfeeding
Clinically significant cardiovascular, hepatic, gastro-intestinal, pulmonary, neurologic, infectious or renal disease or other medical condition that, in the opinion of the physician or Medical Monitor, would preclude participation in the program
Past medical history of compensated or decompensated cirrhosis
Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of maralixibat or its mode of action
Facility Information:
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Stanford University
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Facility Name
Georgetown University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Advent Health
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Facility Name
Children's Healthcare of Atlanta/Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30329
Country
United States
Facility Name
Ann & Robert H. Lurie Children's Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Ochsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
The Children's Hospital at Montefiore
City
New York
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
University of Oklahoma
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
12. IPD Sharing Statement
Links:
URL
https://ghr.nlm.nih.gov/condition/alagille-syndrome
Description
Genetics Home Reference - Alagille syndrome
URL
https://clinicaltrials.gov/ct2/info/fdalinks
Description
US FDA Resources
URL
https://mirumpharma.com
Description
Mirum Pharmaceuticals homepage
URL
https://algseap.com/
Description
Mirum webpage specific to ALGS EAP
Learn more about this trial
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
We'll reach out to this number within 24 hrs